Abstract:
Subjective quality of life (QOL) is becoming a standard health outcome measure especially for people with multiple, chronic, functional, psychological, or incurable illnesses. A good instrument is the pre-requisite of any measurement, which is in the form a questionnaire for QOL. This chapter reviews the concepts, principles, applications, scoring methods and selection criteria of subjective QOL measures to enable users to choose the most appropriate instruments for their purposes.
Quality of life (QOL) is a logical outcome measure of the effectiveness of modern health care much of which aims at relieving suffering and restoring normal living. The essential concepts of QOL measures are subjectivity, multi-dimensionality and well-being. Health-related quality of life (HRQOL) focuses on dimensions that are modifiable by health. General health perception, psychological well-being and functioning are essential dimensions of HRQOL while symptoms and vitality are important causative variables.
Quality of life is a latent variable that cannot be directly measured. It needs to be converted to indicators of its component dimensions and domains to be quantified. To serve the purpose, the indicators must be valid, important, representative and adequate. A QOL measure presents the indicators as items that can be rated on response scales, which are then presented as a profile domain scores or a composite index of quality of life.
Hundreds of QOL measures have been developed mostly for the assessment of HRQOL. Generic measures that are applicable to people with different health status are more suitable for population and comparative studies. Disease specific measures tend to have high sensitivity and are best used for evaluative purposes. Preference-based measures of health (PBMH) convert a multidimensional QOL state to a fractional index for the calculation of quality adjusted life years (QALYs) and cost-effectiveness. A critical appraisal of the nature and psychometric properties of a QOL measure can assure that it will meet the needs of the user.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- COOP/WONCA Charts:
-
The Dartmouth Corporation Functional Health Assessment Charts/World Organization of Family Doctors
- EQ-5D:
-
European Quality of Life-5 Dimension
- HRQOL:
- HUI-3:
-
Health Utilities Index-Mark 3
- ICC:
-
intra-class correlation
- MCID:
- MID:
-
minimally important difference
- PBMH:
-
preference-based measures of health
- PRO:
-
patient reported outcome
- QALYs:
-
quality adjusted life years
- QOL:
-
quality of life
- RS:
-
rating scale
- SD:
-
standard deviation
- SEM:
-
standard error of measurement
- SF-12:
-
The Medical Outcomes Study 12-item Short-form Health Survey
- SF-36:
-
The Medical Outcomes Study 36-item Short-form Health Survey
- SG:
-
standard gamble
- SIP:
-
sickness impact profile
- SRM:
-
standardized response mean
- TTO:
-
time trade-off
- VAS:
-
visual analogue scale
- WHOQOL:
-
World Health Organization Quality of Life Assessment Instrument
References
Aaronson NK, ERORTC Study Group on Quality of Life.(1993). J Natl Cancer Inst. 85: 385–376.ERORTC Study Group on Quality of Life
Bland JM, Altman DG. (1986). Lancet. I: 307–310.
Brazier J, Roberts J, Deverill M. (2002). J Health Econ. 21: 271–292.
Brooks R, EuroQol Group.(1996). Health Policy. 37: 53–72.EuroQol Group
Bullinger M, Anderson R, Cella D, Aaronson N. (1993). Qual Life Res. 2: 451–459.
Clarke PM, Gerdtham UG, Johannesson M, Bingefors K, Smith L. (2002). Soc Sci Med. 55: 1923–1928.
Crosby RD, Kolotkin RL, Williams GR. (2003). J Clin Epidemiol. 56: 395–407.
Efficace F, Bottomley A, Osaba D, Gotay C, Flechtner H, D’haese S, Zurb A. (2003). J Clin Oncol. 21: 3502–3511.
European Medicines Agency Evaluation of Medicines for Human Use (EMEA). (2005). http://www.emea.europe.eu/pdfs/human/ewp/020595en.pdf.
Fan VS, Cartis JR, Tu S, McDonell M, Film SD. (2002). Chest. 122: 429–436.
Fayers PM, Hand DJ. (1997). Qual Life Res. 6: 139–150.
Fayers PM, Sprangers MAG. (2002). The Lancet. 359: 187–188.
FDA. (2006). Guidance for Industry-Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. http://www.fda.gov/cder/guidance/
Feeny D, Furlong W, Torrance GW, Goldsmith CH, Zhu Z, DePauw S, Denton M, Boyle M. (2002). Med Care. 40: 113–128.
Geigle R, Jones SB. (1990). Inquiry. 27: 7–13.
Guyatt GH, King DR, Feeny DH, Stubbing D, Goldstein RS. (1999). J Clin Epidemiol. 52(3): 187–192.
Jaeschke R, Singer J, Guyatt GH. (1989). Control Clin Trials. 10: 407–415.
Juniper EF, Guyatt GH, Willan A, Griffith LE. (1994). J Clin Epidemiol. 47: 81–87.
Kaplan R, Andersen R. (1996). In Spilker B (ed.) Quality of Life and Pharmacoeconomics in Clinical Trials. Lippincott-Raven, Philadelphia, PA, pp. 309–322.
Kazis LE, Anderson JJ, Meenan RF. (1989). Med Care. 27 (Suppl): S178–S189.
Lam CLK, Fong DYT, Lauder IJ, Lam TP. (2002). Soc Sci Med. 55: 1635–1646.
Lam CLK, Lauder IJ, Lam TPD. (2003). Asia Pac Fam Med. 2: 98–106.
Lydick E, Epstein RS. (1993). Qual Life Res. 2: 221–226.
MAPI Research Trust. (2007). PROQOLOD. http://www.proqolid.org/proqolid.
Marks GB, Dunn DM, Woolcock AJ. (1993). J Clin Epidemiol. 46: 1103–1111.
McDowell I, Newell C. (1996). Oxford University Press, New York.
Morimoto T, Fukui T. (2002). J Epidemiol. 12: 160–178.
National Institute for Clinical Excellence (NICE). (2004). http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf.
Oh S, Ku JH. (2006). Qual Life Res. 493–501.
Osoba D, Radrigues G, Myles J, Zee B, Pater J. (1998). J Clin Oncol. 16: 139–144.
Petrie KJ, Weinman J, Sharpe N, Buckley J. (1996). Br Med J. 312: 1191–1194.
Pichard AS, Johnson JA, Feeny D. (2005). Qual Life Res. 14: 207–219.
Reid LD, Tueth MJ, Handberg E, Nyanteh H. (2006). Qual Life Res. 15: 675–686.
Revicki DA, Osoba D, Fairclough D, Barofsky I, Berzon R, Leidy NK, Rothman M. (2000). Qual Life Res. 9: 887–900.
Scholten JHG, van Weel C. (1992). Functional Status Assessment in Family Practice: The Dartmouth COOP Functional Health Assessment Charts/WONCA. Lelystad, Meditekst.
Scientific Advisory Committee of the Medical Outcomes Trust. (2002). Qual life Res. 11: 193–205.
Sousa KH, Kwok O. (2006). Qual Life Res. 15: 725–737.
Torrance GW, Feeny DH. (1989). Intl J Tech Ass in Health Care. 5: 559–575.
van der Molen T, Postma DS, Schreurs AJM, Bosveld HEP, Sears MR, Meyboom de Jong B. (1997). Qual Life Res. 6: 353–361.
Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM. (2004). J Clin Oncol. 22: 714–724.
Von Neumann J, Morgenstern O. (1953). Theory of Games and Economic Behavior. Princeton University Press, Princeton, NJ.
Walters SJ, Brazier JE. (2005). Qual Life Res. 14: 1523–1532.
Ware JE, Kosinski M. (2001). SF-36 Physical & Mental Health Summary Scales: A Manual for Users of Version 1. Quality Metric, Lincoln, Rhode Island.
Ware JE, Snow KK, Kosinski M, Gandek B. (1993). SF-36 Health Survey Manual and Interpretation Guide. The Health Institute, NEMC, Boston.
Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russel LB. (1996). JAMA. 276: 1253–1258.
WHOQOL Group. (1993). Qual Life Res. 2: 153–159.
WHOQOL Group. (1998). Soc Sci Med. 46: 1569–1585.
Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, Erikson P. (2005). Value Health. 8: 94–104.
Wilson IB, Cleary PD. (1995). JAMA. 273(1): 59–65.
Wrywich KW, Bullinger M, Aaronson N, Hays RD, Patrick DL, Symonds T. (2005). Qual Life Res. 14: 285–295.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media LLC
About this entry
Cite this entry
Lam, C.L.K. (2010). Subjective Quality of Life Measures – General Principles and Concepts. In: Preedy, V.R., Watson, R.R. (eds) Handbook of Disease Burdens and Quality of Life Measures. Springer, New York, NY. https://doi.org/10.1007/978-0-387-78665-0_21
Download citation
DOI: https://doi.org/10.1007/978-0-387-78665-0_21
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-78664-3
Online ISBN: 978-0-387-78665-0
eBook Packages: MedicineReference Module Medicine